Yes they are hilarious, but no less maddening. I
Post# of 72440
Good thing the scientists and big pharma folks are not stupid. They are going to see that P outperformed Anacor Pharmaceuticals' topical anti-inflammatory compound, successfully treated patients who were previously unsuccessfully treated with other therapies (biologics and apremilast (Otezla®)), and that P will be a direct competitor in the moderate/severe psoriasis market.
IMO Leo is going to have partners and buyers at his door very soon.